Emergent Biosolutions receives approval to market Biothrax

Emergent Biosolutions receives Paul Ehrlich Intitut (PEI) approval to market their anthrax vaccine in Germany.

PEI announced earlier this month that they had approved Emergent's application to market their anthrax vaccine, Biothrax, This means that Biothrax is the only anthrax vaccine approved by PEI for the prevention of anthrax. Adam Havey, executive vice president and president of the biodefense division of Emergent BioSolutions stated, “[We are] pleased with this first marketing authorization of BioThrax within the European Union. Based on this regulatory approval we look forward to further expanding international registration of BioThrax within the EU to support member states’ efforts to protect their citizens against the threat of anthrax as a biological weapon.”
[Apologies for any confusion, we changed server last week and for reasons best known to the gremlins of the internet the previous incarnation of this story didn't make the swap! Gwyn]

Our Current Sponsors